Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1

European Journal of Cancer Prevention

Volumn 20, Issue 2, 2011, Pages 102-111

  Shim, Jung Hyun ^a   Shin, Ji Ae ^a   Jung, Ji Youn ^b   Choi, Kyeong Hee ^a   Choi, Eun Sun ^a   Cho, Nam Pyo ^a   Kong, Gu ^c   Ryu, Mi Heon ^d   Chae, Jung Ii ^a   Cho, Sung Dae ^a  

^a Chonbuk National University   (South Korea)

^b Kongju National University   (South Korea)

^c Hanyang University   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Apoptosis; cervical cancer; specificity protein 1; tolfenamic acid

Indexed keywords

AMPIROXICAM; CYCLOOXYGENASE 2; MESSENGER RNA; MITHRAMYCIN; PROTEIN P27; RNA; SURVIVIN; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; MICE; MICE, INBRED BALB C; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551571758     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328341e38f     Document Type: Article

References (41)

1. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S (2006). Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98:855-868.
2. Abdelrahim M, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, Cho SD, et al. (2007). Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 67:3286-3294.
3. Agrawal A, Fentiman IS (2008). NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62:444-449.
4. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, et al. (1996). Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556-2560.
5. Bouwman P, Philipsen S (2002). Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 195:27-38.
6. Chen F, Kim E, Wang CC, Harrison LE (2005). Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway. Cell Signal 17:1572-1577.
7. Cheng YH, Imir A, Fenkci V, Yilmaz MB, Bulun SE (2007). Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17bhydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism. Am J Obstet Gynecol 196:391.e1-391.e7.
8. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S (2007). Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 67:2816-2823.
9. Chu S, Ferro TJ (2005). Sp1: regulation of gene expression by phosphorylation. Gene 348:1-11.
10. Chun JY, Hu Y, Pinder E, Wu J, Li F, Gao AC (2007). Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 6:2572-2580.
11. Deniaud E, Baguet J, Mathieu AL, Pages G, Marvel J, Leverrier Y (2006). Overexpression of Sp1 transcription factor induces apoptosis. Oncogene 25:7096-7105.
12. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998). Cyclooxygenase in biology and disease. FASEB J 12:1063-1073.
13. Eskerod O (1994). Gastrointestinal tolerance studies on tolfenamic acid in humans and animals. Pharmacol Toxicol 75 (Suppl 2):44-48.
14. Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J (2007). The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 156 (Suppl 3):25-33.
15. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G (1997). Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15:669-676.
16. Firestone GL, Bjeldanes LF (2003). Indole-3-carbinol and 3-30-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr 133:2448S-2455S.
17. Gately S, Li WW (2004). Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31:2-11.
18. Hansen PE (1994). Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol Toxicol 75 (Suppl 2):81-82.
19. Huang CS, Ho WL, Lee WS, Sheu MT, Wang YJ, Tu SH, et al. (2008). Sp1- regulated p27/Kip1 gene expression is involved in terbinafine-induced human A431 cancer cell differentiation: an in-vitro and in-vivo study. Biochem Pharmacol 75:1783-1796.
20. Jana NR (2008). NSAIDs and apoptosis. Cell Mol Life Sci 65:1295-1301.
21. Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, et al. (2007). Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 97:286-294.
22. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, et al. (2009). Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8:533-542.
23. Kovala-Demertzi D, Hadjipavlou-Litina D, Primikiri A, Staninska M, Kotoglou C, Demertzis MA (2009). Anti-inflammatory, antiproliferative, and radicalscavenging activities of tolfenamic acid and its metal complexes. Chem Biodivers 6:948-960.
24. Lania L, Majello B, De Luca P (1997). Transcriptional regulation by the Sp family proteins. Int J Biochem Cell Biol 29:1313-1323.
25. Lee SH, Bahn JH, Choi CK,Whitlock NC, English AE, Safe S, Baek SJ (2008). ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 7:3739-3750.
26. Liao Z, Mason KA, Milas L (2007). Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs 67:821-845.
27. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. (2001). Overexpression of cyclo-oxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563-18569.
28. Liu B, Qu L, Tao H (2010). Cyclo-oxygenase 2 upregulates the effect of multidrug resistance. Cell Biol Int 34:21-25.
29. Rejholec V, Vapaatalo H, Tokola O, Gothoni G (1979). Tolfenamic acid in the treatment of rheumatoid arthritis. Scand J Rheumatol 24 (Suppl):9-12.
30. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, Kuwano M (1996). Induction of vascular endothelial growth factor by tumor necrosis factor a in human glioma cells: possible roles of SP-1. J Biol Chem 271:28220-28228.
31. Schernhammer ES, Kang JH, Chan AT, Michaud DS, Skinner HG, Giovannucci E, et al. (2004). A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96:22-28.
32. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, et al. (2001). Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61:4143-4154.
33. Stoner M,Wormke M, Saville B, Samudio I, Qin C, Abdelrahim M, Safe S (2004). Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor a and SP proteins. Oncogene 23:1052-1063.
34. Taketo MM (1998). Cyclo-oxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90:1609-1620.
35. Tanwar L, Vaish V, Sanyal SN (2010). Chemopreventive role of etoricoxib (MK- 0663) in experimental colon cancer: induction of mitochondrial proapoptotic factors. Eur J Cancer Prev 19:280-287.
36. Tsujii M, DuBois RN (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501.
37. Wang YT, Chuang JY, Shen MR, Yang WB, Chang WC, Hung JJ (2008). Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. J Mol Biol 380:869-885.
38. Wankya BM, Awadh S, Mwai SJ (1981). Tolfenamic acid and ibuprofen in rheumatoid arthritis: a double blind cross over study. East Afr Med J 58:622-625.
39. Wei D,Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K (2004). Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64:2030-2038.
40. Williams CS, Mann M, DuBois RN (1999). The role of cyclo-oxygenases in inflammation, cancer, and development. Oncogene 18:7908-7916.
41. Zachariae E, Sylvest J (1972). Osteoarthritis of the knee treated with tolfenamic acid. Scand J Rheumatol 1:97-99.